Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2009-08-27 Capital/Financing Update
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce l'initiation de la première étude de Phase II avec l’anticorps monoclonal IPH 2101, soutenue par un nouveau financement d’Oséo de 2,9 mil
Capital/Financing Update Classification · 95% confidence The document is a press release dated August 27, 2009, announcing the initiation of a Phase II clinical study for the monoclonal antibody IPH 2101, supported by new financing from OSEO. It details the study design, the rationale, the disease context (multiple myeloma), and provides company background. This type of announcement, focusing on clinical trial progress and associated funding news, is characteristic of an update related to drug development or financing activities, but it is not a formal regulatory filing like a 10-K or an IR. Since it announces a significant development (Phase II initiation and associated funding), it is best classified as a general corporate announcement. Given the options, 'Capital/Financing Update' (CAP) is relevant due to the mention of the 2.9 million Euro financing, but the primary focus is the clinical trial initiation. 'Regulatory Filings' (RNS) is a broad category for general announcements. However, the content strongly relates to the company's core operations and progress, which often falls under investor relations updates. Since there is no specific category for 'Clinical Trial Progress' or 'Biotech Pipeline Update', and the financing aspect is secondary to the clinical news, I will evaluate the closest fit. The financing aspect (OSEO support) points towards CAP. The clinical trial update itself is often released as a general press release. Given the strong emphasis on the clinical trial initiation and the associated funding, this is a significant corporate event announcement. If the financing was the sole focus, CAP would be perfect. Since it's a mix, and it's a press release format, RNS (Regulatory Filings/General Announcement) is a safe fallback, but CAP captures the financial support aspect. Let's re-examine the definitions. CAP is for 'fundraising, financing activities, or capital structure changes'. The OSEO advance is a financing activity. Therefore, CAP is the most specific fit capturing the financial support aspect tied to the clinical progress announcement.
2009-08-27 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the start of the first Phase II clinical trial with monoclonal antibody IPH 2101 supported by a new 2.9 million euros financing from
Capital/Financing Update Classification · 98% confidence The document is a press release dated August 27, 2009, announcing the approval to start a Phase IIa clinical trial for a drug candidate (IPH 2101) and the securing of a significant financing grant (2.9 million Euros) from OSEO to support this trial. This content directly relates to corporate financing activities and updates on clinical development progress, which falls under Capital/Financing Update (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). Since it announces new funding secured for development, CAP is the most appropriate classification.
2009-08-27 English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce les résultats de son assemblée générale mixte ainsi que des changements dans la composition de son Conseil de Surveillance
AGM Information Classification · 99% confidence The document is titled "INNATE PHARMA ANNONCE LES RÉSULTATS DES VOTES DE SON ASSEMBLÉE GÉNÉRALE, AINSI QUE DES CHANGEMENTS DANS LA COMPOSITION DE SON CONSEIL DE SURVEILLANCE" (Innate Pharma announces the results of its General Meeting votes, as well as changes in the composition of its Supervisory Board). It explicitly details the voting results from the Annual General Meeting (AGM) held on June 23, 2009, and announces the appointment of a new board member and the departure of another. This content directly aligns with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA) and also contains elements of 'Board/Management Information' (MANG). Since the primary focus is the official results of the shareholder vote from the AGM, DVA is the most specific and appropriate classification. The document is a formal announcement, not a presentation (AGM-R) or a proxy solicitation document (PSI).
2009-06-23 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the outcome of its annual general meeting, including changes in the composition of its Supervisory Board
AGM Information Classification · 99% confidence The document is explicitly titled "INNATE PHARMA ANNOUNCES THE OUTCOME OF ITS ANNUAL GENERAL MEETING, INCLUDING CHANGES IN THE COMPOSITION OF ITS SUPERVISORY BOARD". It details the results of the AGM held on June 23, 2009, including the appointment of new board members and the departure of another. This content directly aligns with the description of an Annual General Meeting (AGM) outcome announcement. Therefore, the appropriate classification is AGM-R.
2009-06-23 English
Innate Pharma SA et ses partenaires annoncent le démarrage opérationnel de PLATINE, plateforme commune d’immunomonitoring
Regulatory Filings Classification · 95% confidence The document is a press release dated June 15, 2009, announcing the operational start of 'PLATINE,' a common platform for immunomonitoring established by several biotech companies and research institutions (Innate Pharma, Transgene, ImmunID, Inserm, Centre Léon-Bérard). The text details the purpose, location, funding, and quotes from management regarding this new venture. This type of announcement, detailing strategic operational developments, partnerships, or the launch of a new business unit/platform, does not fit neatly into the specific financial reporting categories (10-K, IR, ER, etc.). It is a general corporate announcement. Given the options, it is best classified as a general Regulatory Filing (RNS) as a fallback for significant, non-standard corporate news, or potentially a Capital/Financing Update (CAP) if the platform launch involved significant new capital structuring, but the primary focus is operational news. Since it is a press release announcing a strategic operational development rather than a formal regulatory filing like a 10-K or a specific financial event like a dividend or earnings release, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate category.
2009-06-15 French
Innate Pharma SA and its partners announced the operational start of PLATINE, a joint immuno-monitoring platform
Regulatory Filings Classification · 95% confidence The document is a press release dated June 15, 2009, announcing the operational start of a joint immuno-monitoring platform named Platine by several biotechnology companies and research institutions. It details the purpose, location, and initial activities of this platform. This type of announcement, which is a general corporate update regarding a new venture or operational milestone, does not fit the specific definitions for financial reports (10-K, IR, ER), shareholder actions (DIV, DVA), or management changes (MANG). Since it is a general corporate announcement that doesn't fit a more specific category like Capital/Financing (CAP) or Legal Proceedings (LTR), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings), as it serves as a public disclosure of a significant operational event.
2009-06-15 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.